DelMar Pharmaceuticals Presents Positive Data on the Benefit of VAL-083 in...
VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 6, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the...
View ArticleAbbVie's Commitment to Oncology Demonstrated at the 57th American Society of...
NORTH CHICAGO, Ill., Nov. 5, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a leading biopharmaceutical company, will present data from clinical trials evaluating the company's oncology portfolio during the...
View ArticleIMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2016 RESULTS AND CLINICAL PROGRAM...
(Source: Immunomedics Inc) Microsoft Word - IMMUNOMEDICS ANNOUNCES FIRST QUARTER FISCAL 2016 RESULTS IMMUNOMEDICS,® INC. 300 The American Road, Morris Plains, New Jersey 07950 ¤ (973) 605-8200 ¤ Fax...
View ArticleAbbVie's Commitment to Oncology Demonstrated at the 57th American Society of...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 5, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a leading biopharmaceutical company, will present data from clinical trials evaluating the company's oncology...
View ArticleIdera Pharmaceuticals Presents Preclinical Data Demonstrating Potent...
CAMBRIDGE, Mass. and EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing Toll-like receptor (TLR) and RNA...
View ArticleAffimed Presents Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC
HEIDELBERG, Germany, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq:AFMD), a clinical-stage biopharmaceutical company developing highly targeted cancer immunotherapies, yesterday presented first...
View ArticleFive Prime Therapeutics Reports Third Quarter 2015 Results and Provides...
(Source: Five Prime Therapeutics Inc) November 4, 2015 Established license and collaboration agreement with Bristol-Myers Squibb for FPA008: $1.74 billion in upfront and milestone payments,...
View ArticleBellicum Announces Data Presentations on Lead Product Candidate BPX-501 and...
(Source: Bellicum Pharmaceuticals Inc) Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T and TCR Pipeline Programs at the 57th American Society of Hematology (ASH)...
View ArticleBasilea to present preclinical brain tumor stem cell data on its oncology...
(Source: Basilea Pharmaceutica AG) Tumor check point controller BAL101553 demonstrates inhibitory activity on tumor stem cell self-renewal and invasion in models of brain cancer Loss of glioblastoma...
View ArticleAffimed Presents Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC...
(Source: Affimed NV) 7fbc2669-d166-4590-8138-1a241acda2ea.pdf FOR IMMEDIATE RELEASE Affimed Presents Data on Potency of NK- and T-cell EGFRvIII TandAbs at SITC -- NK- and T-cell TandAbs Demonstrate...
View ArticleBioLineRx Announces Positive Clinical Results from First Part of Phase 2...
(Source: BioLineRX Ltd) - Data strongly suggest BL-8040 has potent anti-leukemic activity in combination with Ara-C in AML - - Results to be presented at 2015 ASH Annual Meeting - TEL AVIV,...
View ArticleAmgen Highlights Data To Be Presented At 2015 American College Of...
THOUSAND OAKS, Calif., Nov. 4, 2015 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present key results from several studies related to Enbrel® (etanercept) and ABP 501, an adalimumab...
View ArticleCytomX and MD Anderson Cancer Center Enter Into Strategic Collaboration for...
(Source: The University of Texas MD Anderson Cancer Center) Collaboration Combines Leading Research in Chimeric Antigen Receptor (CAR) Natural Killer (NK) Cell Therapies with CytomX's Probody Platform...
View ArticleCelldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015...
(Source: Celldex Therapeutics Inc) November 6, 2015 -- Preclinical data suggest cancers vary in sensitivity to mechanisms of CD27 immune modulation -- -- Clinical experience with varlilumab is...
View ArticleSeattle Genetics Announces More Than 20 Presentations at ASH 2015...
(Source: Seattle Genetics Inc) -ADCETRIS Data Featured in 17 Presentations, Including Eight Oral Presentations, Support Goal to Establish ADCETRIS as the Foundation of Therapy for CD30-Expressing...
View ArticleCelldex Presents Varlilumab Mechanism Data at SITC Annual Meeting 2015
-- Preclinical data suggest cancers vary in sensitivity to mechanisms of CD27 immune modulation -- -- Clinical experience with varlilumab is consistent with immune co-stimulation and regulatory T cell...
View Articlebluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121...
(Source: Bluebird Bio Inc) – Six abstracts accepted for presentation – – Interim data on LentiGlobin in beta-thalassemia show six of six evaluable non-β 0 /β 0 patients are transfusion-independent as...
View ArticleJanssen to Showcase Growing Portfolio with More Than 40 Data Presentations at...
RARITAN, N.J., Nov. 5, 2015 /PRNewswire/ -- At the 57th American Society of Hematology (ASH) Annual Meeting, Janssen Research & Development, LLC will present new data for both approved and...
View ArticleMorphoSys Announces Presentations at Upcoming American Society of Hematology...
(Source: MorphoSys AG) November 05, 2015 / 4:30 pm, CET MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced upcoming presentations of data on the Company's proprietary...
View ArticleApexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate...
SAN CARLOS, Calif., Nov. 6, 2015 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of...
View Article